SI2234614T1 - Farmacevtska zmes za parenteralno administracijo ultra-kratko delujočega blokatorja beta-adrenoreceptorja - Google Patents
Farmacevtska zmes za parenteralno administracijo ultra-kratko delujočega blokatorja beta-adrenoreceptorjaInfo
- Publication number
- SI2234614T1 SI2234614T1 SI200830850T SI200830850T SI2234614T1 SI 2234614 T1 SI2234614 T1 SI 2234614T1 SI 200830850 T SI200830850 T SI 200830850T SI 200830850 T SI200830850 T SI 200830850T SI 2234614 T1 SI2234614 T1 SI 2234614T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pharmaceutical composition
- parenteral administration
- acting beta
- adrenoreceptor antagonist
- ultrashort acting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT21072007 | 2007-12-21 | ||
EP08863830A EP2234614B1 (de) | 2007-12-21 | 2008-12-22 | Pharmazeutische zusammensetzung zur parenteralen verabreichung eines ultrakurzwirksamen beta-adrenorezeptor antagonisten |
PCT/AT2008/000470 WO2009079679A2 (de) | 2007-12-21 | 2008-12-22 | Pharmazeutische zusammensetzung |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2234614T1 true SI2234614T1 (sl) | 2013-01-31 |
Family
ID=40634349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200830850T SI2234614T1 (sl) | 2007-12-21 | 2008-12-22 | Farmacevtska zmes za parenteralno administracijo ultra-kratko delujočega blokatorja beta-adrenoreceptorja |
Country Status (15)
Country | Link |
---|---|
US (5) | US20100311738A1 (sl) |
EP (1) | EP2234614B1 (sl) |
JP (1) | JP5623288B2 (sl) |
CN (1) | CN101903024A (sl) |
AU (1) | AU2008340179B2 (sl) |
CA (1) | CA2712414C (sl) |
CY (1) | CY1114951T1 (sl) |
DK (1) | DK2234614T3 (sl) |
ES (1) | ES2397126T3 (sl) |
HR (1) | HRP20121045T1 (sl) |
NZ (1) | NZ586200A (sl) |
PL (1) | PL2234614T3 (sl) |
PT (1) | PT2234614E (sl) |
SI (1) | SI2234614T1 (sl) |
WO (1) | WO2009079679A2 (sl) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104379134A (zh) | 2012-05-10 | 2015-02-25 | Aop孤儿药品股份公司 | 肠外艾司洛尔剂型 |
EP2796139A1 (en) | 2013-04-26 | 2014-10-29 | AOP Orphan Pharmaceuticals AG | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU575153B2 (en) * | 1984-04-09 | 1988-07-21 | Du Pont Merck Pharmaceutical Company, The | Pharmaceutical compositions and method for treatment for prophylaxis of cardiac disorders |
US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US4857552A (en) | 1988-06-08 | 1989-08-15 | E. I. Du Pont De Nemours And Co. | Stable pharmaceutical composition |
DE4207922A1 (de) | 1992-03-13 | 1993-09-23 | Pharmatech Gmbh | Wasserloesliche einschlussverbindungen und verfahren zu deren herstellung |
AU672862B2 (en) * | 1992-12-02 | 1996-10-17 | Insite Vision Incorporated | Cyclodextrin and polymer based drug delivery system |
WO2001037845A1 (en) | 1999-11-23 | 2001-05-31 | Aderis Pharmaceuticals, Inc. | Treatment of heart rhythm disturbances with n6-substituted-5'-(n-substituted) carboxamidoadenosines |
TWI277414B (en) * | 2001-01-12 | 2007-04-01 | Baxter Int | Esmolol formulation |
WO2003028718A1 (en) * | 2001-10-01 | 2003-04-10 | Smithkline Beecham Corporation | Novel formulations of carvedilol |
EP1443969A2 (en) | 2001-10-18 | 2004-08-11 | Decode Genetics EHF | Non-inclusion cyclodextrin complexes |
WO2003088978A1 (en) * | 2002-04-18 | 2003-10-30 | Cv Therapeutics, Inc. | Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside |
US7148211B2 (en) * | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
EP1417962A1 (de) | 2002-11-06 | 2004-05-12 | AOP Orphan Pharmaceuticals AG | Verfahren zur Herstellung eines Arzneimittels enthaltend Esmolol |
US7893040B2 (en) * | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
CN1827109A (zh) * | 2006-04-14 | 2006-09-06 | 北京润德康医药技术有限公司 | 一种以兰洛地尔及其盐为活性成分的冻干粉针制剂及其制备工艺 |
US8722736B2 (en) * | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
-
2008
- 2008-12-22 PT PT88638309T patent/PT2234614E/pt unknown
- 2008-12-22 CN CN200880122163XA patent/CN101903024A/zh active Pending
- 2008-12-22 PL PL08863830T patent/PL2234614T3/pl unknown
- 2008-12-22 WO PCT/AT2008/000470 patent/WO2009079679A2/de active Application Filing
- 2008-12-22 JP JP2010538268A patent/JP5623288B2/ja active Active
- 2008-12-22 NZ NZ586200A patent/NZ586200A/en unknown
- 2008-12-22 DK DK08863830.9T patent/DK2234614T3/da active
- 2008-12-22 ES ES08863830T patent/ES2397126T3/es active Active
- 2008-12-22 AU AU2008340179A patent/AU2008340179B2/en active Active
- 2008-12-22 SI SI200830850T patent/SI2234614T1/sl unknown
- 2008-12-22 EP EP08863830A patent/EP2234614B1/de active Active
- 2008-12-22 CA CA2712414A patent/CA2712414C/en active Active
- 2008-12-22 US US12/809,927 patent/US20100311738A1/en not_active Abandoned
-
2012
- 2012-12-18 HR HRP20121045AT patent/HRP20121045T1/hr unknown
- 2012-12-20 CY CY20121101243T patent/CY1114951T1/el unknown
-
2016
- 2016-08-26 US US15/248,845 patent/US20160361422A1/en not_active Abandoned
-
2018
- 2018-10-19 US US16/164,926 patent/US10660964B2/en active Active
-
2020
- 2020-04-28 US US16/860,336 patent/US11517624B2/en active Active
-
2022
- 2022-12-05 US US18/061,562 patent/US20230277674A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2008340179A1 (en) | 2009-07-02 |
JP5623288B2 (ja) | 2014-11-12 |
US11517624B2 (en) | 2022-12-06 |
CY1114951T1 (el) | 2016-12-14 |
CA2712414A1 (en) | 2009-07-02 |
CA2712414C (en) | 2016-07-12 |
US20160361422A1 (en) | 2016-12-15 |
JP2011506486A (ja) | 2011-03-03 |
US10660964B2 (en) | 2020-05-26 |
EP2234614A2 (de) | 2010-10-06 |
WO2009079679A2 (de) | 2009-07-02 |
PT2234614E (pt) | 2013-01-25 |
DK2234614T3 (da) | 2013-02-11 |
AU2008340179B2 (en) | 2014-10-23 |
US20190046646A1 (en) | 2019-02-14 |
US20100311738A1 (en) | 2010-12-09 |
NZ586200A (en) | 2012-06-29 |
EP2234614B1 (de) | 2012-10-17 |
WO2009079679A3 (de) | 2009-11-26 |
US20230277674A1 (en) | 2023-09-07 |
ES2397126T3 (es) | 2013-03-04 |
US20200323988A1 (en) | 2020-10-15 |
HRP20121045T1 (hr) | 2013-01-31 |
CN101903024A (zh) | 2010-12-01 |
PL2234614T3 (pl) | 2013-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1164059A1 (en) | Compositions for drug administration | |
IL218928A (en) | Corticosteroids for oral administration | |
ZA200807721B (en) | Anti-cancer pharmaceutical composition | |
IL207512A0 (en) | Pharmaceutical composition for poorly soluble drugs | |
IL194642A0 (en) | Antagonist anti-cd40 antibody pharmaceutical compositions | |
HK1198287A1 (en) | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives 2--1- | |
GB2454567B (en) | Anti-malarial pharmaceutical composition | |
HK1209649A1 (en) | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives 2--1- | |
IL217927A (en) | Azahetrocyclic compounds and their containing pharmaceutical preparations | |
ZA201105572B (en) | Pharmaceutical composition for oral administration | |
IL195857A0 (en) | Pharmaceutical compositions for treating psychological conditions comprising muscarinic receptor m1 antagonists | |
IL208325A0 (en) | Stabilizing lipis compositions for oral pharmaceutical agents | |
HK1139052A1 (en) | Composition for transdermal administration | |
SI2234614T1 (sl) | Farmacevtska zmes za parenteralno administracijo ultra-kratko delujočega blokatorja beta-adrenoreceptorja | |
IL196099A0 (en) | Pharmaceutical composition for administration by injection | |
ZA201102405B (en) | Pharmaceutical composition for oral administration | |
EP2520300A4 (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | |
PL2410997T3 (pl) | Kompozycja do podawania polimerycznych leków |